Metropolitan Life Insurance Company (MetLife)’s Cogent Biosciences COGT Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,461	Closed	-$23.3K	–	475
2024 Q1	$23.3K	Buy	3,461 +161	+5%	+$995	﹤0.01%	1785
2023 Q4	$19.4K	Sell	3,300 -1,430	-30%	-$11K	﹤0.01%	1935
2023 Q3	$46.1K	Buy	4,730 +1,172	+33%	+$13.9K	﹤0.01%	1447
2023 Q2	$42.1K	Buy	+3,558	New	+$40.8K	﹤0.01%	1522
2023 Q1	–	Sell	-3,857	Closed	-$44.6K	–	2341
2022 Q4	$44.6K	Hold	3,857	–	–	﹤0.01%	1547
2022 Q3	$57.5K	Buy	3,857 +1,218	+46%	+$16.7K	﹤0.01%	1359
2022 Q2	$23.8K	Hold	2,639	–	–	﹤0.01%	1959
2022 Q1	$19.8K	Sell	2,639 -8,012	-75%	-$55.8K	﹤0.01%	2105
2021 Q4	$91.4K	Buy	10,651 +42	+0.4%	+$365	﹤0.01%	2533
2021 Q3	$89.2K	Buy	+10,609	New	+$81.3K	﹤0.01%	2589

Other funds holding COGT

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s COGT Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Cogent Biosciences (COGT) in Q2 2024, closing a stake of 3,461 shares — an estimated $23.3K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in COGT in Q3 2021 and held it in 10 quarters. The position peaked at $91.4K in Q4 2021. 148 funds tracked by Wall St. Rank hold COGT as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Cogent Biosciences position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 3,461 Cogent Biosciences shares in Q2 2024, an estimated $23.3K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Cogent Biosciences in Q3 2021 and held it in 10 quarters.
Metropolitan Life Insurance Company (MetLife)'s Cogent Biosciences position peaked at $91.4K in Q4 2021.
148 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.